Table 6 Associations of PAPP-A2 with IGF-1, IGF-1:IGFBP-3 molar ratio and IGFBP-2 with additional adjustment for other members of the system.
n | β per 0.05 ng/mL PAPP-A2 increment | 95% CI | |
---|---|---|---|
IGF-1, ng/ml | |||
As in Table 5 | 394 | − 4.3 | (− 7.0, − 1.6) |
- Plus adjustment for IGFBP-2 | 394 | − 3.8 | (− 6.5, − 1.0) |
- Plus adjustment for IGFBP-3 | 394 | − 3.1 | (− 5.6, − 0.7) |
In participants with available IGFBP-1 | 360 | 4.0 | (− 6.8, − 1.2) |
- Plus adjustment for IGFBP-1 (log-transformed) | 360 | − 3.3 | (− 5.9, − 0.6) |
In participants with available IGFBP-5 | 125 | − 2.6 | (− 7.5, 2.2) |
- Plus adjustment for IGFBP-5 (log-transformed) | 125 | − 2.4 | (− 7.2, 2.4) |
In participants with available free IGF-1 | 125 | − 4.5 | (− 7.4, − 1.6) |
- Plus adjustment for free IGF-1 (log-transformed) | 339 | − 4.3 | (− 7.2, − 1.3) |
IGF-1/IGFBP-3 molar ratio, % | |||
As in Table 5 | 394 | - 0.34 | (− 0.59, − 0.09) |
- Plus adjustment for IGFBP-2 | 394 | − 0.35 | (− 0.60, − 0.09) |
In participants with available IGFBP-1 | 360 | - 0.33 | (− 0.58, − 0.08) |
- Plus adjustment for IGFBP-1 (log-transformed) | 360 | − 0.29 | (− 0.53, − 0.04) |
In participants with available IGFBP-5 | 125 | - 0.13 | (− 0.58, 0.32) |
- Plus adjustment for IGFBP-5 (log-transformed) | 125 | − 0.11 | (− 0.55, 0.33) |
In participants with available free IGF-1 | 339 | − 0.37 | (− 0.64, − 0.09) |
- Plus adjustment for free IGF-1 (log-transformed) | 339 | − 0.37 | (− 0.64, − 0.10) |
IGFBP-2, ng/ml | |||
As in Table 5 | 394 | 11.9 | (5.0, 18.8) |
- Plus adjustment for IGFBP-3 | 394 | 10.3 | (3.6, 17.1) |
- Plus adjustment for IGF-1 | 394 | 10.7 | (3.7, 17.6) |
In participants with available free IGF-1 | 339 | 11.1 | (4.0, 18.2) |
- Plus adjustment for free IGF-1 (log-transformed) | 339 | 11.1 | (4.1, 18.1) |
- Plus adjustment for free to total IGF-1 (%, log-transformed) | 339 | 11.5 | (4.4, 18.5) |
In participants with available IGFBP-1 | 360 | 10.9 | (3.7, 18.0) |
- Plus adjustment for IGFBP-1 (log-transformed) | 360 | 9.2 | (2.3, 16.2) |
In participants with available IGFBP-5 | 125 | 4.9 | (− 7.1, 17.0) |
- Plus adjustment for IGFBP5 (log-transformed) | 125 | 5.2 | (− 6.9, 17.2) |